nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—ORM1—Vemurafenib—melanoma	0.209	0.347	CbGbCtD
Prazosin—ABCB1—melanoma	0.159	1	CbGaD
Prazosin—ABCG2—Vemurafenib—melanoma	0.127	0.212	CbGbCtD
Prazosin—CYP1A1—Dacarbazine—melanoma	0.0902	0.15	CbGbCtD
Prazosin—ABCG2—Dactinomycin—melanoma	0.0847	0.141	CbGbCtD
Prazosin—ABCG2—Docetaxel—melanoma	0.0437	0.0727	CbGbCtD
Prazosin—ABCB1—Dactinomycin—melanoma	0.0305	0.0508	CbGbCtD
Prazosin—ABCB1—Docetaxel—melanoma	0.0158	0.0262	CbGbCtD
Prazosin—HTR1D—meninx—melanoma	0.0128	0.423	CbGeAlD
Prazosin—Vasculitis—Vemurafenib—melanoma	0.00214	0.0349	CcSEcCtD
Prazosin—MT3—head—melanoma	0.00149	0.0491	CbGeAlD
Prazosin—KCNH7—head—melanoma	0.00149	0.0491	CbGeAlD
Prazosin—HTR1D—blood vessel—melanoma	0.00146	0.048	CbGeAlD
Prazosin—CYP1A1—skin epidermis—melanoma	0.00136	0.0449	CbGeAlD
Prazosin—Urinary incontinence—Carmustine—melanoma	0.00107	0.0174	CcSEcCtD
Prazosin—KCNH6—head—melanoma	0.00106	0.035	CbGeAlD
Prazosin—MT3—lymph node—melanoma	0.00104	0.0344	CbGeAlD
Prazosin—Urinary incontinence—Temozolomide—melanoma	0.00103	0.0168	CcSEcCtD
Prazosin—Gynaecomastia—Carmustine—melanoma	0.00099	0.0161	CcSEcCtD
Prazosin—Alopecia—Vemurafenib—melanoma	0.000928	0.0151	CcSEcCtD
Prazosin—Eye pain—Carmustine—melanoma	0.00089	0.0145	CcSEcCtD
Prazosin—Eye pain—Temozolomide—melanoma	0.00086	0.014	CcSEcCtD
Prazosin—Nasal congestion—Temozolomide—melanoma	0.000852	0.0139	CcSEcCtD
Prazosin—Arthralgia—Vemurafenib—melanoma	0.000779	0.0127	CcSEcCtD
Prazosin—HTR1D—eye—melanoma	0.000775	0.0255	CbGeAlD
Prazosin—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00068	0.0111	CcSEcCtD
Prazosin—Sweating increased—Temozolomide—melanoma	0.000653	0.0106	CcSEcCtD
Prazosin—Fatigue—Vemurafenib—melanoma	0.000643	0.0105	CcSEcCtD
Prazosin—Constipation—Vemurafenib—melanoma	0.000638	0.0104	CcSEcCtD
Prazosin—Pollakiuria—Temozolomide—melanoma	0.00062	0.0101	CcSEcCtD
Prazosin—Erectile dysfunction—Temozolomide—melanoma	0.000618	0.01	CcSEcCtD
Prazosin—ADRA1B—head—melanoma	0.000601	0.0198	CbGeAlD
Prazosin—SLC22A3—mammalian vulva—melanoma	0.000593	0.0195	CbGeAlD
Prazosin—Flushing—Bleomycin—melanoma	0.000591	0.0096	CcSEcCtD
Prazosin—Body temperature increased—Vemurafenib—melanoma	0.00059	0.00959	CcSEcCtD
Prazosin—ADRA1D—head—melanoma	0.000588	0.0194	CbGeAlD
Prazosin—Alopecia—Bleomycin—melanoma	0.000562	0.00915	CcSEcCtD
Prazosin—Hallucination—Carmustine—melanoma	0.000553	0.00899	CcSEcCtD
Prazosin—Flushing—Dactinomycin—melanoma	0.000551	0.00896	CcSEcCtD
Prazosin—Hypersensitivity—Vemurafenib—melanoma	0.00055	0.00894	CcSEcCtD
Prazosin—Asthenia—Vemurafenib—melanoma	0.000535	0.00871	CcSEcCtD
Prazosin—Hallucination—Temozolomide—melanoma	0.000534	0.00869	CcSEcCtD
Prazosin—Pruritus—Vemurafenib—melanoma	0.000528	0.00859	CcSEcCtD
Prazosin—Alopecia—Dactinomycin—melanoma	0.000525	0.00853	CcSEcCtD
Prazosin—Flushing—Carmustine—melanoma	0.000516	0.00838	CcSEcCtD
Prazosin—Ill-defined disorder—Bleomycin—melanoma	0.000514	0.00836	CcSEcCtD
Prazosin—Diarrhoea—Vemurafenib—melanoma	0.000511	0.0083	CcSEcCtD
Prazosin—Tinnitus—Temozolomide—melanoma	0.000501	0.00814	CcSEcCtD
Prazosin—Malaise—Bleomycin—melanoma	0.0005	0.00812	CcSEcCtD
Prazosin—Flushing—Temozolomide—melanoma	0.000498	0.0081	CcSEcCtD
Prazosin—Dizziness—Vemurafenib—melanoma	0.000494	0.00803	CcSEcCtD
Prazosin—Alopecia—Carmustine—melanoma	0.000491	0.00798	CcSEcCtD
Prazosin—Ill-defined disorder—Dactinomycin—melanoma	0.000479	0.0078	CcSEcCtD
Prazosin—Vomiting—Vemurafenib—melanoma	0.000475	0.00772	CcSEcCtD
Prazosin—Alopecia—Temozolomide—melanoma	0.000474	0.00771	CcSEcCtD
Prazosin—ABCB1—blood vessel—melanoma	0.000474	0.0156	CbGeAlD
Prazosin—Orthostatic hypotension—Docetaxel—melanoma	0.000471	0.00766	CcSEcCtD
Prazosin—Rash—Vemurafenib—melanoma	0.000471	0.00765	CcSEcCtD
Prazosin—Dermatitis—Vemurafenib—melanoma	0.00047	0.00764	CcSEcCtD
Prazosin—Headache—Vemurafenib—melanoma	0.000468	0.0076	CcSEcCtD
Prazosin—Discomfort—Bleomycin—melanoma	0.000466	0.00758	CcSEcCtD
Prazosin—Malaise—Dactinomycin—melanoma	0.000466	0.00758	CcSEcCtD
Prazosin—Terazosin—ABCB1—melanoma	0.000463	0.573	CrCbGaD
Prazosin—Vision blurred—Carmustine—melanoma	0.000456	0.00741	CcSEcCtD
Prazosin—Oedema—Bleomycin—melanoma	0.000452	0.00735	CcSEcCtD
Prazosin—SLC22A1—head—melanoma	0.000444	0.0146	CbGeAlD
Prazosin—Nausea—Vemurafenib—melanoma	0.000443	0.00721	CcSEcCtD
Prazosin—Vision blurred—Temozolomide—melanoma	0.00044	0.00716	CcSEcCtD
Prazosin—HTR1D—head—melanoma	0.00044	0.0145	CbGeAlD
Prazosin—Discomfort—Dactinomycin—melanoma	0.000435	0.00707	CcSEcCtD
Prazosin—Angina pectoris—Docetaxel—melanoma	0.000435	0.00707	CcSEcCtD
Prazosin—Ill-defined disorder—Temozolomide—melanoma	0.000434	0.00705	CcSEcCtD
Prazosin—SLC22A3—head—melanoma	0.000424	0.014	CbGeAlD
Prazosin—CYP1A1—skin of body—melanoma	0.000422	0.0139	CbGeAlD
Prazosin—Oedema—Dactinomycin—melanoma	0.000422	0.00686	CcSEcCtD
Prazosin—Malaise—Temozolomide—melanoma	0.000421	0.00685	CcSEcCtD
Prazosin—Vertigo—Temozolomide—melanoma	0.00042	0.00683	CcSEcCtD
Prazosin—Palpitations—Temozolomide—melanoma	0.000413	0.00672	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Bleomycin—melanoma	0.000412	0.0067	CcSEcCtD
Prazosin—Paraesthesia—Bleomycin—melanoma	0.000406	0.0066	CcSEcCtD
Prazosin—ABCG2—mammalian vulva—melanoma	0.000406	0.0134	CbGeAlD
Prazosin—Dyspnoea—Bleomycin—melanoma	0.000403	0.00656	CcSEcCtD
Prazosin—Arthralgia—Temozolomide—melanoma	0.000398	0.00647	CcSEcCtD
Prazosin—Oedema—Carmustine—melanoma	0.000395	0.00642	CcSEcCtD
Prazosin—Discomfort—Temozolomide—melanoma	0.000393	0.00639	CcSEcCtD
Prazosin—Dry mouth—Temozolomide—melanoma	0.000389	0.00633	CcSEcCtD
Prazosin—Pain—Bleomycin—melanoma	0.000387	0.00629	CcSEcCtD
Prazosin—CYP1A1—mammalian vulva—melanoma	0.000385	0.0127	CbGeAlD
Prazosin—Tachycardia—Carmustine—melanoma	0.000385	0.00626	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000384	0.00625	CcSEcCtD
Prazosin—Oedema—Temozolomide—melanoma	0.000381	0.0062	CcSEcCtD
Prazosin—Epistaxis—Docetaxel—melanoma	0.000375	0.0061	CcSEcCtD
Prazosin—Feeling abnormal—Bleomycin—melanoma	0.000373	0.00606	CcSEcCtD
Prazosin—Hyperhidrosis—Temozolomide—melanoma	0.000369	0.006	CcSEcCtD
Prazosin—HTR1A—head—melanoma	0.000367	0.0121	CbGeAlD
Prazosin—Fatigue—Dactinomycin—melanoma	0.000364	0.00591	CcSEcCtD
Prazosin—Pain—Dactinomycin—melanoma	0.000361	0.00586	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Carmustine—melanoma	0.00036	0.00585	CcSEcCtD
Prazosin—Urticaria—Bleomycin—melanoma	0.000359	0.00584	CcSEcCtD
Prazosin—ADRA2A—mammalian vulva—melanoma	0.000359	0.0118	CbGeAlD
Prazosin—Body temperature increased—Bleomycin—melanoma	0.000357	0.00581	CcSEcCtD
Prazosin—Insomnia—Carmustine—melanoma	0.000357	0.0058	CcSEcCtD
Prazosin—Paraesthesia—Carmustine—melanoma	0.000354	0.00576	CcSEcCtD
Prazosin—Dyspnoea—Carmustine—melanoma	0.000352	0.00572	CcSEcCtD
Prazosin—Somnolence—Carmustine—melanoma	0.000351	0.00571	CcSEcCtD
Prazosin—Feeling abnormal—Dactinomycin—melanoma	0.000348	0.00565	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Temozolomide—melanoma	0.000348	0.00565	CcSEcCtD
Prazosin—Insomnia—Temozolomide—melanoma	0.000345	0.00561	CcSEcCtD
Prazosin—Doxazosin—ABCB1—melanoma	0.000345	0.426	CrCbGaD
Prazosin—Paraesthesia—Temozolomide—melanoma	0.000343	0.00557	CcSEcCtD
Prazosin—Dyspnoea—Temozolomide—melanoma	0.00034	0.00553	CcSEcCtD
Prazosin—ORM1—lymph node—melanoma	0.000339	0.0112	CbGeAlD
Prazosin—Somnolence—Temozolomide—melanoma	0.000339	0.00551	CcSEcCtD
Prazosin—ADRA1A—head—melanoma	0.000338	0.0111	CbGeAlD
Prazosin—Constipation—Carmustine—melanoma	0.000338	0.00549	CcSEcCtD
Prazosin—Pain—Carmustine—melanoma	0.000338	0.00549	CcSEcCtD
Prazosin—Body temperature increased—Dactinomycin—melanoma	0.000333	0.00542	CcSEcCtD
Prazosin—Hypersensitivity—Bleomycin—melanoma	0.000333	0.00542	CcSEcCtD
Prazosin—Flushing—Docetaxel—melanoma	0.000331	0.00539	CcSEcCtD
Prazosin—Fatigue—Temozolomide—melanoma	0.000329	0.00535	CcSEcCtD
Prazosin—KCNH2—head—melanoma	0.000326	0.0108	CbGeAlD
Prazosin—Constipation—Temozolomide—melanoma	0.000326	0.0053	CcSEcCtD
Prazosin—Pain—Temozolomide—melanoma	0.000326	0.0053	CcSEcCtD
Prazosin—Feeling abnormal—Carmustine—melanoma	0.000325	0.00529	CcSEcCtD
Prazosin—Asthenia—Bleomycin—melanoma	0.000324	0.00528	CcSEcCtD
Prazosin—Pruritus—Bleomycin—melanoma	0.00032	0.0052	CcSEcCtD
Prazosin—Alopecia—Docetaxel—melanoma	0.000315	0.00513	CcSEcCtD
Prazosin—Feeling abnormal—Temozolomide—melanoma	0.000314	0.00511	CcSEcCtD
Prazosin—Body temperature increased—Carmustine—melanoma	0.000312	0.00507	CcSEcCtD
Prazosin—Hypersensitivity—Dactinomycin—melanoma	0.000311	0.00505	CcSEcCtD
Prazosin—Urticaria—Temozolomide—melanoma	0.000303	0.00493	CcSEcCtD
Prazosin—Asthenia—Dactinomycin—melanoma	0.000303	0.00492	CcSEcCtD
Prazosin—Body temperature increased—Temozolomide—melanoma	0.000302	0.0049	CcSEcCtD
Prazosin—SLC22A3—lymph node—melanoma	0.000297	0.00979	CbGeAlD
Prazosin—Hypersensitivity—Carmustine—melanoma	0.000291	0.00473	CcSEcCtD
Prazosin—Diarrhoea—Dactinomycin—melanoma	0.000289	0.00469	CcSEcCtD
Prazosin—Vomiting—Bleomycin—melanoma	0.000287	0.00467	CcSEcCtD
Prazosin—Rash—Bleomycin—melanoma	0.000285	0.00464	CcSEcCtD
Prazosin—Dermatitis—Bleomycin—melanoma	0.000285	0.00463	CcSEcCtD
Prazosin—Asthenia—Carmustine—melanoma	0.000283	0.0046	CcSEcCtD
Prazosin—Hypersensitivity—Temozolomide—melanoma	0.000281	0.00457	CcSEcCtD
Prazosin—Syncope—Docetaxel—melanoma	0.000279	0.00453	CcSEcCtD
Prazosin—CYP1A1—head—melanoma	0.000276	0.00908	CbGeAlD
Prazosin—Palpitations—Docetaxel—melanoma	0.000275	0.00447	CcSEcCtD
Prazosin—Asthenia—Temozolomide—melanoma	0.000274	0.00445	CcSEcCtD
Prazosin—Loss of consciousness—Docetaxel—melanoma	0.000273	0.00444	CcSEcCtD
Prazosin—Diarrhoea—Carmustine—melanoma	0.00027	0.00439	CcSEcCtD
Prazosin—Pruritus—Temozolomide—melanoma	0.00027	0.00439	CcSEcCtD
Prazosin—Nausea—Bleomycin—melanoma	0.000269	0.00437	CcSEcCtD
Prazosin—Vomiting—Dactinomycin—melanoma	0.000268	0.00436	CcSEcCtD
Prazosin—Rash—Dactinomycin—melanoma	0.000266	0.00432	CcSEcCtD
Prazosin—Arthralgia—Docetaxel—melanoma	0.000265	0.0043	CcSEcCtD
Prazosin—Dizziness—Carmustine—melanoma	0.000261	0.00424	CcSEcCtD
Prazosin—Diarrhoea—Temozolomide—melanoma	0.000261	0.00424	CcSEcCtD
Prazosin—Dry mouth—Docetaxel—melanoma	0.000259	0.00421	CcSEcCtD
Prazosin—ADRA2A—head—melanoma	0.000257	0.00847	CbGeAlD
Prazosin—Oedema—Docetaxel—melanoma	0.000254	0.00412	CcSEcCtD
Prazosin—Dizziness—Temozolomide—melanoma	0.000252	0.0041	CcSEcCtD
Prazosin—Vomiting—Carmustine—melanoma	0.000251	0.00408	CcSEcCtD
Prazosin—Nausea—Dactinomycin—melanoma	0.00025	0.00407	CcSEcCtD
Prazosin—ABCB1—retina—melanoma	0.00025	0.00824	CbGeAlD
Prazosin—Shock—Docetaxel—melanoma	0.00025	0.00406	CcSEcCtD
Prazosin—Rash—Carmustine—melanoma	0.000249	0.00405	CcSEcCtD
Prazosin—Dermatitis—Carmustine—melanoma	0.000249	0.00404	CcSEcCtD
Prazosin—Tachycardia—Docetaxel—melanoma	0.000248	0.00403	CcSEcCtD
Prazosin—Headache—Carmustine—melanoma	0.000247	0.00402	CcSEcCtD
Prazosin—Vomiting—Temozolomide—melanoma	0.000243	0.00394	CcSEcCtD
Prazosin—Rash—Temozolomide—melanoma	0.00024	0.00391	CcSEcCtD
Prazosin—Dermatitis—Temozolomide—melanoma	0.00024	0.00391	CcSEcCtD
Prazosin—Headache—Temozolomide—melanoma	0.000239	0.00389	CcSEcCtD
Prazosin—Nausea—Carmustine—melanoma	0.000234	0.00381	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Docetaxel—melanoma	0.000231	0.00376	CcSEcCtD
Prazosin—Insomnia—Docetaxel—melanoma	0.000229	0.00373	CcSEcCtD
Prazosin—KCNH2—lymph node—melanoma	0.000229	0.00753	CbGeAlD
Prazosin—Paraesthesia—Docetaxel—melanoma	0.000228	0.0037	CcSEcCtD
Prazosin—Nausea—Temozolomide—melanoma	0.000227	0.00368	CcSEcCtD
Prazosin—Dyspnoea—Docetaxel—melanoma	0.000226	0.00368	CcSEcCtD
Prazosin—Somnolence—Docetaxel—melanoma	0.000225	0.00367	CcSEcCtD
Prazosin—Fatigue—Docetaxel—melanoma	0.000219	0.00356	CcSEcCtD
Prazosin—Constipation—Docetaxel—melanoma	0.000217	0.00353	CcSEcCtD
Prazosin—Pain—Docetaxel—melanoma	0.000217	0.00353	CcSEcCtD
Prazosin—Feeling abnormal—Docetaxel—melanoma	0.000209	0.0034	CcSEcCtD
Prazosin—ABCG2—lymph node—melanoma	0.000203	0.0067	CbGeAlD
Prazosin—Body temperature increased—Docetaxel—melanoma	0.000201	0.00326	CcSEcCtD
Prazosin—ABCB1—mammalian vulva—melanoma	0.0002	0.00659	CbGeAlD
Prazosin—CYP1A1—lymph node—melanoma	0.000193	0.00636	CbGeAlD
Prazosin—Hypersensitivity—Docetaxel—melanoma	0.000187	0.00304	CcSEcCtD
Prazosin—Asthenia—Docetaxel—melanoma	0.000182	0.00296	CcSEcCtD
Prazosin—ADRA2A—lymph node—melanoma	0.00018	0.00593	CbGeAlD
Prazosin—Pruritus—Docetaxel—melanoma	0.000179	0.00292	CcSEcCtD
Prazosin—Diarrhoea—Docetaxel—melanoma	0.000174	0.00282	CcSEcCtD
Prazosin—Dizziness—Docetaxel—melanoma	0.000168	0.00273	CcSEcCtD
Prazosin—Vomiting—Docetaxel—melanoma	0.000161	0.00262	CcSEcCtD
Prazosin—Rash—Docetaxel—melanoma	0.00016	0.0026	CcSEcCtD
Prazosin—Dermatitis—Docetaxel—melanoma	0.00016	0.0026	CcSEcCtD
Prazosin—Headache—Docetaxel—melanoma	0.000159	0.00258	CcSEcCtD
Prazosin—Nausea—Docetaxel—melanoma	0.000151	0.00245	CcSEcCtD
Prazosin—ABCB1—head—melanoma	0.000143	0.00472	CbGeAlD
Prazosin—ABCB1—lymph node—melanoma	0.0001	0.0033	CbGeAlD
Prazosin—CYP1A1—Metabolism—PIK3CG—melanoma	5.64e-06	3.84e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—MAPK3—melanoma	5.62e-06	3.83e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CASP3—melanoma	5.6e-06	3.82e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL2—melanoma	5.6e-06	3.81e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—ERBB2—melanoma	5.58e-06	3.8e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NOTCH1—melanoma	5.57e-06	3.8e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—IL6—melanoma	5.57e-06	3.8e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—VEGFA—melanoma	5.56e-06	3.79e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—FGF2—melanoma	5.56e-06	3.79e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PTEN—melanoma	5.52e-06	3.76e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—BRAF—melanoma	5.51e-06	3.76e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—STAT3—melanoma	5.5e-06	3.75e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CB—melanoma	5.5e-06	3.75e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—NRAS—melanoma	5.49e-06	3.74e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—PIK3CA—melanoma	5.48e-06	3.74e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTEN—melanoma	5.46e-06	3.72e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MDM2—melanoma	5.46e-06	3.72e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CD80—melanoma	5.46e-06	3.72e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CCND1—melanoma	5.46e-06	3.72e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KIT—melanoma	5.45e-06	3.71e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CG—melanoma	5.45e-06	3.71e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—APC—melanoma	5.45e-06	3.71e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—NRAS—melanoma	5.45e-06	3.71e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PPARG—melanoma	5.44e-06	3.71e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CTNNB1—melanoma	5.4e-06	3.68e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGF—melanoma	5.38e-06	3.67e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—ERBB2—melanoma	5.38e-06	3.67e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IGF1—melanoma	5.37e-06	3.66e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—MAPK1—melanoma	5.34e-06	3.64e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—EGFR—melanoma	5.34e-06	3.64e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CB—melanoma	5.31e-06	3.62e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MMP9—melanoma	5.3e-06	3.61e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CXCL8—melanoma	5.29e-06	3.6e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CDKN1A—melanoma	5.28e-06	3.6e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PTEN—melanoma	5.27e-06	3.59e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK3—melanoma	5.26e-06	3.58e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—HRAS—melanoma	5.25e-06	3.58e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—NFKB1—melanoma	5.24e-06	3.57e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—PIK3CA—melanoma	5.22e-06	3.56e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—MAPK3—melanoma	5.22e-06	3.56e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MDM2—melanoma	5.2e-06	3.54e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAP2K1—melanoma	5.19e-06	3.54e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CDKN1B—melanoma	5.16e-06	3.52e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CD—melanoma	5.15e-06	3.51e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—AKT1—melanoma	5.14e-06	3.5e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—ERBB2—melanoma	5.13e-06	3.49e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—BRAF—melanoma	5.12e-06	3.49e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MYC—melanoma	5.11e-06	3.48e-05	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—AKT1—melanoma	5.11e-06	3.48e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	5.11e-06	3.48e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CXCL8—melanoma	5.1e-06	3.48e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTEN—melanoma	5.09e-06	3.47e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—HRAS—melanoma	5.07e-06	3.46e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CASP3—melanoma	5.06e-06	3.45e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CB—melanoma	5.06e-06	3.45e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL2—melanoma	5.05e-06	3.44e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—KRAS—melanoma	5.05e-06	3.44e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—IL6—melanoma	5.03e-06	3.43e-05	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—AKT1—melanoma	5.02e-06	3.42e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK1—melanoma	5e-06	3.41e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—EGFR—melanoma	5e-06	3.41e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CB—melanoma	4.99e-06	3.4e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IGF1—melanoma	4.99e-06	3.4e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CDKN1B—melanoma	4.98e-06	3.4e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—MAPK1—melanoma	4.96e-06	3.38e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—EGFR—melanoma	4.96e-06	3.38e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CD—melanoma	4.96e-06	3.38e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTGS2—melanoma	4.95e-06	3.37e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—FGF2—melanoma	4.94e-06	3.36e-05	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—AKT1—melanoma	4.93e-06	3.36e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CCND1—melanoma	4.93e-06	3.36e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—ALB—melanoma	4.89e-06	3.34e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CASP3—melanoma	4.88e-06	3.33e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CTNNB1—melanoma	4.88e-06	3.32e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL2—melanoma	4.88e-06	3.32e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CXCL8—melanoma	4.86e-06	3.31e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—IL6—melanoma	4.85e-06	3.31e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—HRAS—melanoma	4.83e-06	3.29e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAP2K1—melanoma	4.82e-06	3.29e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CD—melanoma	4.79e-06	3.26e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MMP9—melanoma	4.78e-06	3.26e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CDKN1A—melanoma	4.76e-06	3.25e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—VEGFA—melanoma	4.76e-06	3.24e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CCND1—melanoma	4.75e-06	3.24e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PTEN—melanoma	4.75e-06	3.24e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CDKN1B—melanoma	4.75e-06	3.24e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	4.74e-06	3.23e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—NFKB1—melanoma	4.73e-06	3.22e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—KRAS—melanoma	4.72e-06	3.22e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—STAT3—melanoma	4.71e-06	3.21e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CTNNB1—melanoma	4.71e-06	3.21e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—NRAS—melanoma	4.7e-06	3.2e-05	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—AKT1—melanoma	4.7e-06	3.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—KRAS—melanoma	4.69e-06	3.2e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CASP3—melanoma	4.65e-06	3.17e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL2—melanoma	4.65e-06	3.17e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—AKT1—melanoma	4.64e-06	3.16e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	4.64e-06	3.16e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—IL6—melanoma	4.62e-06	3.15e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MDM2—melanoma	4.62e-06	3.15e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MMP9—melanoma	4.62e-06	3.15e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CDKN1A—melanoma	4.6e-06	3.13e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PTEN—melanoma	4.59e-06	3.13e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—FGF2—melanoma	4.59e-06	3.13e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NFKB1—melanoma	4.57e-06	3.11e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—ERBB2—melanoma	4.55e-06	3.1e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CCND1—melanoma	4.53e-06	3.09e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CG—melanoma	4.51e-06	3.07e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK3—melanoma	4.5e-06	3.07e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CB—melanoma	4.49e-06	3.06e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CTNNB1—melanoma	4.48e-06	3.06e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—AKT1—melanoma	4.48e-06	3.05e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MMP9—melanoma	4.4e-06	3e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CDKN1A—melanoma	4.38e-06	2.99e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MYC—melanoma	4.38e-06	2.98e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PTEN—melanoma	4.37e-06	2.98e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NFKB1—melanoma	4.35e-06	2.96e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PPARG—melanoma	4.35e-06	2.96e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—PIK3CA—melanoma	4.34e-06	2.96e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CB—melanoma	4.32e-06	2.95e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CXCL8—melanoma	4.32e-06	2.94e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTEN—melanoma	4.31e-06	2.94e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	4.31e-06	2.94e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—VEGFA—melanoma	4.29e-06	2.93e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MDM2—melanoma	4.29e-06	2.92e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—HRAS—melanoma	4.29e-06	2.92e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTGS2—melanoma	4.28e-06	2.92e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK1—melanoma	4.28e-06	2.92e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—EGFR—melanoma	4.28e-06	2.92e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—AKT1—melanoma	4.26e-06	2.91e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—STAT3—melanoma	4.25e-06	2.9e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—NRAS—melanoma	4.24e-06	2.89e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ERBB2—melanoma	4.23e-06	2.88e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN1B—melanoma	4.22e-06	2.87e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TP53—melanoma	4.2e-06	2.86e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CB—melanoma	4.17e-06	2.84e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—AKT1—melanoma	4.17e-06	2.84e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—VEGFA—melanoma	4.15e-06	2.83e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CASP3—melanoma	4.13e-06	2.82e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL2—melanoma	4.13e-06	2.81e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—IL6—melanoma	4.11e-06	2.8e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—STAT3—melanoma	4.1e-06	2.8e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NRAS—melanoma	4.09e-06	2.79e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK3—melanoma	4.06e-06	2.77e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KRAS—melanoma	4.04e-06	2.76e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CCND1—melanoma	4.02e-06	2.74e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—HRAS—melanoma	4.02e-06	2.74e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CXCL8—melanoma	4.01e-06	2.73e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—HRAS—melanoma	3.99e-06	2.72e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CTNNB1—melanoma	3.98e-06	2.71e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CD—melanoma	3.96e-06	2.7e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MYC—melanoma	3.95e-06	2.69e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—VEGFA—melanoma	3.95e-06	2.69e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK3—melanoma	3.92e-06	2.67e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN1B—melanoma	3.92e-06	2.67e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—ALB—melanoma	3.91e-06	2.66e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—STAT3—melanoma	3.91e-06	2.66e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MMP9—melanoma	3.9e-06	2.66e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NRAS—melanoma	3.9e-06	2.66e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PIK3CA—melanoma	3.89e-06	2.65e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN1A—melanoma	3.89e-06	2.65e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PTEN—melanoma	3.88e-06	2.65e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—AKT1—melanoma	3.88e-06	2.64e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK1—melanoma	3.87e-06	2.63e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—EGFR—melanoma	3.86e-06	2.63e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NFKB1—melanoma	3.86e-06	2.63e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PIK3CA—melanoma	3.85e-06	2.63e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IL6—melanoma	3.84e-06	2.62e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CASP3—melanoma	3.84e-06	2.62e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL2—melanoma	3.83e-06	2.61e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—IL6—melanoma	3.81e-06	2.6e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MYC—melanoma	3.81e-06	2.6e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—AKT1—melanoma	3.79e-06	2.58e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCND1—melanoma	3.74e-06	2.55e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTEN—melanoma	3.73e-06	2.55e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK3—melanoma	3.73e-06	2.55e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK1—melanoma	3.73e-06	2.54e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—EGFR—melanoma	3.73e-06	2.54e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PIK3CA—melanoma	3.71e-06	2.53e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CTNNB1—melanoma	3.7e-06	2.52e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KRAS—melanoma	3.65e-06	2.49e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MYC—melanoma	3.63e-06	2.48e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MMP9—melanoma	3.63e-06	2.47e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN1A—melanoma	3.62e-06	2.46e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTEN—melanoma	3.61e-06	2.46e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TP53—melanoma	3.59e-06	2.45e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CA—melanoma	3.59e-06	2.45e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NFKB1—melanoma	3.59e-06	2.45e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK1—melanoma	3.55e-06	2.42e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EGFR—melanoma	3.55e-06	2.42e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—AKT1—melanoma	3.55e-06	2.42e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KRAS—melanoma	3.52e-06	2.4e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—AKT1—melanoma	3.52e-06	2.4e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—VEGFA—melanoma	3.51e-06	2.39e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—STAT3—melanoma	3.47e-06	2.37e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NRAS—melanoma	3.46e-06	2.36e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CB—melanoma	3.45e-06	2.35e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—HRAS—melanoma	3.44e-06	2.34e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTGS2—melanoma	3.42e-06	2.33e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KRAS—melanoma	3.36e-06	2.29e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CA—melanoma	3.35e-06	2.29e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK3—melanoma	3.32e-06	2.26e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL6—melanoma	3.29e-06	2.24e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—VEGFA—melanoma	3.26e-06	2.22e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TP53—melanoma	3.24e-06	2.21e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CA—melanoma	3.24e-06	2.21e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MYC—melanoma	3.23e-06	2.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—STAT3—melanoma	3.23e-06	2.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NRAS—melanoma	3.22e-06	2.19e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—AKT1—melanoma	3.18e-06	2.17e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK1—melanoma	3.16e-06	2.15e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EGFR—melanoma	3.16e-06	2.15e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—AKT1—melanoma	3.15e-06	2.14e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TP53—melanoma	3.13e-06	2.13e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—HRAS—melanoma	3.1e-06	2.11e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CA—melanoma	3.08e-06	2.1e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK3—melanoma	3.08e-06	2.1e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CA—melanoma	3.04e-06	2.07e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—AKT1—melanoma	3.03e-06	2.07e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MYC—melanoma	3e-06	2.04e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—HRAS—melanoma	3e-06	2.04e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTEN—melanoma	2.98e-06	2.03e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TP53—melanoma	2.98e-06	2.03e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KRAS—melanoma	2.98e-06	2.03e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL6—melanoma	2.97e-06	2.02e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—AKT1—melanoma	2.93e-06	2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK1—melanoma	2.93e-06	2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGFR—melanoma	2.93e-06	2e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL6—melanoma	2.87e-06	1.95e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—HRAS—melanoma	2.85e-06	1.94e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KRAS—melanoma	2.77e-06	1.89e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—AKT1—melanoma	2.74e-06	1.87e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CA—melanoma	2.74e-06	1.87e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL6—melanoma	2.73e-06	1.86e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TP53—melanoma	2.65e-06	1.81e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—AKT1—melanoma	2.64e-06	1.8e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CA—melanoma	2.63e-06	1.8e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CA—melanoma	2.54e-06	1.73e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—HRAS—melanoma	2.53e-06	1.73e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—AKT1—melanoma	2.52e-06	1.72e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—AKT1—melanoma	2.49e-06	1.69e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TP53—melanoma	2.46e-06	1.68e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6—melanoma	2.43e-06	1.65e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—HRAS—melanoma	2.35e-06	1.6e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6—melanoma	2.25e-06	1.54e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—AKT1—melanoma	2.24e-06	1.52e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—AKT1—melanoma	2.15e-06	1.47e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CA—melanoma	2.1e-06	1.43e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—AKT1—melanoma	2.08e-06	1.42e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—AKT1—melanoma	1.72e-06	1.17e-05	CbGpPWpGaD
